On January 5, 2022 Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, reported that its Chief Executive Officer, Patrick Amstutz, Ph.D., will participate in several upcoming healthcare investor events in January, 2022 (Press release, Molecular Partners, JAN 5, 2022, View Source [SID1234598352]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Presentation Details:

H.C. Wainwright BioConnect 2022 Conference

Monday, January 10, 2022 at 12:00 pm ET (6:00 pm CET); on-demand on January 10-13, 2022
JP Morgan 40th Annual Virtual Healthcare Conference

Wednesday, January 12, 2022 at 7:30 am ET (1:30 pm CET)
Baader Helvea Swiss Equities Conference

Wednesday, January 12, 2022 at 10:30 am ET (4:30 pm CET)
Conference Participation Details:

The Octavian Seminar 2022

Friday, January 14, 2022
All webcasted presentations will be made available on the Molecular Partners website.